A pilot study of the safety and efficacy of thymosin α1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy

Clinical and Experimental Immunology

Volumn 134, Issue 3, 2003, Pages 477-481

  Chadwick, D ^a   Pido Lopez, J ^b   Pires, A ^b   Imami, N ^b   Gotch, F ^b   Villacian, J S ^a   Ravindran, S ^a   Paton, N I ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

CD4; HIV; Immune reconstitution; Thymopoiesis; Thymosin 1

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; T LYMPHOCYTE RECEPTOR; THYMOSIN ALPHA1;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE SUBSETS; LYMPHOPOIESIS; MIDDLE AGED; PILOT PROJECTS; THYMOSIN; VIRAL LOAD;

EID: 0348012900     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2003.02331.x     Document Type: Article

References (31)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Valdez H, Chowdhry TK, Asaad R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis 2001; 32:1487-93.
3. + T lymphocyte counts and patterns of mortality among patients infected with human immunodeficiency virus who were enrolled in community programs for clinical research on AIDS. Clin Infect Dis 1996; 22:513-20.
4. Floridia M, Fragola V, Galluzzo CM et al. HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of <50 cells/microL): an analysis of 338 clinical events from a randomized clinical trial. HIV Med 2002; 3:75-84.
5. Goldstein AL, Low TL, McAdoo M et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA 1977; 74:725-9.
6. Zatz MM, Goldstein AL. Mechanism of action of thymosin. I. Thymosin fraction 5 increases lymphokine production by mature murine T cells responding in a mixed lymphocyte reaction. J Immunol 1985; 134:1032-8.
7. Sztein MB, Serrate SA, Goldstein AL. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci USA 1986; 83:6107-11.
8. Hsia J, Sztein MB, Naylor PH et al. Modulation of thymosin alpha 1 and thymosin beta 4 levels and peripheral blood mononuclear cell subsets during experimental rhinovirus colds. Lymphokine Res 1989; 8:383-91.
9. Hadden JW, Saha A, Sosa M et al. Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hydrocortisone-treated aged mice. Int J Immunopharmacol 1995; 17:821-8.
10. Favalli C, Mastino A, Jezzi T et al. Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice. Int J Immunopharmacol 1989; 11:443-50.
11. + thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Mech Ageing Dev 1997; 94:85-101.
12. Baumann CA, Badamchian M, Goldstein AL. Thymosin alpha1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro. Int J Immunopharmacol 2000; 22:1057-66.
13. + cells in an in vitro thymic epithelia organ coculture model. Int J Immunopharmacol 1999; 21:15-26.
14. Roy R, Singh SM, Shanker A et al. Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host: the molecular events involved and their inhibition by thymosin alpha-1. Int J Immunopharmacol 2000; 22:309-21.
15. Giuliani C, Napolitano G, Mastino A et al. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol 2000; 30:778-86.
16. Ramachandran R, Katzenstein DA, Winters MA et al. Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. J Infect Dis 1996; 173:1005-8.
17. Garaci E, Rocchi G, Perroni L et al. Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection. Int J Clin Lab Res 1994; 24:23-8.
18. 3. Antiviral Ther 1998; 3:103-11.
19. Pido-Lopez J, Pires A, Nelson M et al. Thymic activity in late-stage HIV-1 infected individuals receiving highly active antiretroviral therapy: potential effect of steroid therapy. HIV Med 2002; 3:56-61.
20. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
21. Douek DC, McFarland RD, Keiser PH et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396:690-5.
22. Pido-Lopez J, Imami N, Aspinall R. Both age and gender affect thymic output: more recent thymic migrants in females than males as they age. Clin Exp Immunol 2001; 125:409-13.
23. Lau GK, Nanji A, Hou J et al. Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J Viral Hepat 2002; 9:280-7.
24. Teixeira L, Valdez H, McCune JM et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. Aids 2001; 15:1749-56.
25. Imami N, Hardy G, Burton C et al. Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination. Immunol Lett 2001; 79:63-76.
26. Al-Harthi L, Marchetti G, Steffens CM et al. Detection of T cell receptor circles (TRECs) as biomarkers for de novo T cell synthesis using a quantitative polymerase chain reaction-enzyme linked immunosorbent assay (PCR-ELISA). J Immunol Meth 2000; 237:187-97.
27. Hatzakis A, Touloumi G, Karanicolas R et al. Effect of recent thymic emigrants on progression of HIV-1 disease. Lancet 2000; 355: 599-604.
28. Steffens CM, Smith KY, Landay A et al. T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals. AIDS 2001; 15:1757-64.
29. Mussini C, Pinti M, Borghi V et al. Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy. AIDS 2002; 16:1609-16.
30. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 2000; 192:557-64.
31. Cho BK, Rao VP, Ge Q et al. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 2000; 192:549-56.